🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

RecruitingPhase 1Ages 18 Years - anyAllOno Pharmaceutical Co., Ltd.
NCT07787208 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors. 2. Participants who are refractory or intolerant to standard therapy. 3. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1. 4. Participants with tumor tissue samples available for biomarker testing. Exclusion Criteria: 1. Participants with a history or presence of severe hypersensitivity to any other antibody agents. 2. Participants with pericardial fluid, pleural effusion or ascites requiring treatment 3. Participants with uncontrolled tumor-related pain 4. Participants with severe peritoneal dissemination. 5. Participants with multiple primary cancers. 6. Participants with a history or presence of ILD or pulmonary fibrosis.
💊

What it tests

  • ONO-7429
📍

Where

10 sites
National Cancer Center Hospital East
Kashiwa, Japan
Gunma University Hospital
Maebashi, Japan
Niigata Cancer Center Hospital
Niigata, Japan
Kansai Medical University Hospital
Hirakata, Japan
Osaka International Cancer Institute
Osaka, Japan
Kindai University Hospital
Sakai, Japan
Saitama Medical University International Medical Center
Hidaka, Japan
Shizuoka Cancer Center
Sunto-gun, Japan

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy